Patriot Financial Group Insurance Agency LLC purchased a new position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 24,950 shares of the company’s stock, valued at approximately $136,000.
Other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. lifted its position in shares of Maravai LifeSciences by 1,172.4% during the third quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock worth $33,658,000 after purchasing an additional 3,731,924 shares during the last quarter. Point72 DIFC Ltd bought a new position in Maravai LifeSciences during the third quarter worth $22,108,000. Millennium Management LLC increased its stake in Maravai LifeSciences by 12.3% during the second quarter. Millennium Management LLC now owns 5,968,592 shares of the company’s stock valued at $42,735,000 after purchasing an additional 653,639 shares during the last quarter. Royce & Associates LP grew its position in shares of Maravai LifeSciences by 130.4% during the 3rd quarter. Royce & Associates LP now owns 908,778 shares of the company’s stock valued at $7,552,000 after buying an additional 514,332 shares during the last quarter. Finally, Quantinno Capital Management LP raised its stake in Maravai LifeSciences by 610.2% during the third quarter. Quantinno Capital Management LP now owns 336,527 shares of the company’s stock worth $2,797,000 after acquiring an additional 289,141 shares during the period. 50.25% of the stock is owned by institutional investors and hedge funds.
Maravai LifeSciences Stock Performance
Shares of MRVI opened at $5.03 on Thursday. The firm has a market capitalization of $1.27 billion, a PE ratio of -3.07 and a beta of -0.07. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The firm has a 50-day moving average price of $5.42 and a 200 day moving average price of $7.20. Maravai LifeSciences Holdings, Inc. has a 52-week low of $4.28 and a 52-week high of $11.56.
Analyst Ratings Changes
MRVI has been the subject of several recent research reports. Guggenheim began coverage on Maravai LifeSciences in a report on Thursday, December 19th. They set a “neutral” rating for the company. Robert W. Baird dropped their target price on Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Royal Bank of Canada cut their target price on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a research note on Friday, November 8th. William Blair restated a “market perform” rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Finally, Wolfe Research began coverage on shares of Maravai LifeSciences in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $10.28.
Check Out Our Latest Report on Maravai LifeSciences
Insider Transactions at Maravai LifeSciences
In other Maravai LifeSciences news, insider Carl Hull acquired 175,000 shares of the stock in a transaction dated Monday, November 11th. The shares were bought at an average price of $5.64 per share, with a total value of $987,000.00. Following the purchase, the insider now directly owns 175,000 shares of the company’s stock, valued at approximately $987,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.63% of the company’s stock.
Maravai LifeSciences Profile
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Articles
- Five stocks we like better than Maravai LifeSciences
- What is the Dogs of the Dow Strategy? Overview and Examples
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Investing in Commodities: What Are They? How to Invest in Them
- 3 Steel Stocks Soaring After Tariff Announcements
- Top Stocks Investing in 5G Technology
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Want to see what other hedge funds are holding MRVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Free Report).
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.